WG
BLPH

Winton Group’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Winton Group’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,498
Closed -$127K – 1620
2020
Q3 		$127K Buy
+12,498
New +$147K ﹤0.01% 1383

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Winton Group's BLPH Position: Q4 2020 in Review

Winton Group sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2020, closing a stake of 12,498 shares — an estimated $127K sold.

Winton Group first reported a position in BLPH in Q3 2020 and held it in 1 quarter. The position peaked at $127K in Q3 2020. 37 funds tracked by Wall St. Rank hold BLPH as of Q4 2020.

  • Winton Group reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Winton Group sold 12,498 Bellerophon Therapeutics, Inc. shares in Q4 2020, an estimated $127K.
  • Winton Group first reported a position in Bellerophon Therapeutics, Inc. in Q3 2020 and held it in 1 quarter.
  • Winton Group's Bellerophon Therapeutics, Inc. position peaked at $127K in Q3 2020.
  • 37 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2020.

Based on Winton Group's 13F filing for Q4 2020, filed 12 Feb 2021.